Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1596-1603

  Segura Pacheco, Blanca ^a   Trejo Becerril, Catalina ^a   Perez Cardenas, Enrique ^a   Taja Chayeb, Lucia ^a   Mariscal, Ignacio ^a   Chavez, Alma ^a   Acuña, Carmen ^a   Salazar, Ana Maria ^a   Lizano, Marcela ^a   Dueñas Gonzalez, Alfonso ^a,b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ESTROGEN RECEPTOR; HYDRALAZINE; PROCAINAMIDE; PROTEIN P16; RETINOIC ACID RECEPTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA METHYLATION; DRUG ACTIVITY; DRUG SCREENING; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE INDUCTION; HEAD CANCER; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOUSE; NECK CANCER; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BREAST NEOPLASMS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; HYDRALAZINE; MICE; MICE, NUDE; PROCAINAMIDE; RECEPTORS, ESTROGEN; RECEPTORS, RETINOIC ACID; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 10744225448     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Baylin, S. B., and Herman, J. G. DNA hypermethylation in tumorigenesis: epigenetics joints genetics. Trends Genet., 16: 168-174, 2000.
2. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
3. Sakai, T., Toguchida, J., Ohtani, N., Yandell, D. W., Rapaport, J. M., and Dryja, T. P. Allele-specific hypermethylation of the retinoblastoma tumor suppressor gene. Am. J. Hum. Genet., 48: 880-888, 1991.
4. Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D. S., Gnarra, J. R., Linehan, W. M., and Baylin, S. B. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA, 91: 9700-9704, 1994.
5. Graff, J. R., Herman, J. G., Lapidus, R. G., Chopra, H., Xu, R., Jarrard, D. F., Isaacs, W. B., Pitha, P. M., Davidson, N. E., and Baylin, S. B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinoma. Cancer Res., 55: 5195-5199, 1995.
6. Kane, M. F., Loda, M., Gaida, G. M., Lipman, J., Mishra, R., Goldman, H., Jessup, J. M., and Kolodner, R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res., 57: 808-811, 1997.
7. Esteller, M., Silva, J. M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., Bussaglia, E., Prat, J., Harkes, I. C., Repasky, E. A., Gabrielson, E., Schutte, M., Baylin, S. B., and Herman, J. G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. (Bethesda), 92: 564-569, 2000.
8. Ferguson, T., Lapidus, R. G., Baylin, S. B., and Davidson, N. E. Demethylation of the estrogen receptor gene in estrogen receptornegative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res., 55: 2279-2283, 1995.
9. Bird, A. P. CpG islands and the function of DNA methylation. Nature (Lond.), 321: 209-213, 1986.
10. Migeon, B. R. Insights into X chromosome inactivation from studies of species variation. DNA methylation and replication, and vice versa. Genet. Res., 56: 91-98, 1990.
11. Li. E., Beard, C., and Jaenisch, R. Role for DNA methylation in genomic imprinting. Nature (Lond.), 366: 362-365, 1993.
12. Schuler, M., Herrmann, R., De Greve, J. L., Stewart, A. K., Garzemeier, U., Stewart, D. J., Laufman, L., Gralla, R., Kuball, J., Buhl, R., Heussel, C. P., Kommoss, F., Perruchoud, A. P., Shepherd, F. A., Fritz, M. A., Horowithz, J. A., Huber, C., and Rochlitz, C. Adenovirusmediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small cell lung cancer: results of a multicenter Phase II study. J. Clin. Oncol., 19: 1750-1758, 2001.
13. Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., and Cotter, F. E. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol., 18: 1809-1811, 2000.
14. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1084-1086, 2001.
15. Hainsworth, J. D. Rituximab as first-line systemic therapy for patients with low-grade lymphoma. Semin. Oncol., 27 (Suppl. 12): 25-29, 2000.
16. Bender, C. M., Pao, M. M., and Jones, P. A. Inhibition of DNA methylation by 5-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res., 58: 95-101, 1998.
17. Wu, J., Issa, J. P., Herman, J., Bassett, D. E., Nelking, B. D., and Baylin, S. B. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH3T3 cells. Proc. Natl. Acad. Sci. USA, 90: 8891-8895, 1993.
18. Ramchandani, S., MacLeod, A. R., Pinard, M., Von Hofe, E., and Szyf, M. Inhibition of tumorigenesis by a cytosine-DNA methyltransferase, antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA, 94: 684-689, 1997.
19. Santini, V., Kartarjian, H. M., and Issa, J. P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann. Intern. Med., 134: 573-586, 2001.
20. Yung, R., Chang, S., Hemati, N., Johnson, K., and Richardson, B. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum., 40: 1436-1443, 1997.
21. Kaplan, M. J., Deng, C., Yang, J., and Richardson, B. C. DNA methylation in the regulation of T cell LFA-1 expression. Immunol. Investig., 29: 411-425, 2000.
22. Knowlden, J., Gee, J. M. W., Bryant, S., McClelland, R. A., Manning, D. L., Mansel, R., Ellis, I. O., Blarney, R. W., Robertson, J. F. R., and Nicholson, R. I. Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. Clin. Cancer Res., 3: 2165-2172, 1997.
23. Gonzalgo, M. L., Bender, C. M., You, E. H., Glendening, J. M., Flores, J. F., Walker, G. J., Hayward, N. K., Jones, P. A., and Fountain, J. W. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res., 57: 5336-5347, 1997.
24. Sirchia, S. M., Ferguson, A. T., Sironi, E., Subramanyan, S., Orlandi, R., Sukumar, S., and Sacchi, N. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene, 19: 1556-1563, 2000.
25. Iwase, H., Omoto, Y., Iwata, H., Toyama, T., Hara, Y., Ando, Y., Ito, Y., Fujii, Y., and Kobayashi, S. DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers. Br. J. Cancer, 80: 1982-1986, 1999.
26. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
27. Cote, S., Sinnett, D., and Momparler, R. L. Demethylation by 5-aza-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor β gene in human colon carcinoma cells. Anti-Cancer Drugs, 9: 743-750, 1998.
28. Ley, T. J., Desimone, J., Anagnou, N. P., Keller, G. H., Humphries, R. K., Turner, P. H., Young, N. S., Heller, P., and Nienhius, A. W. 5-Azacytidine selectively increases δ-globin synthesis in a patient with B Thalasemia. N. Engl. J. Med., 307: 1469-1475, 1982.
29. Ottaviano, R. G., Issa, J-P., Parl, F. F., Smith, H. S., Baylin, S. B., and Davidson, N. E. Methylation of the estrogen receptor CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res., 54: 2552-2555, 1994.
30. Lapidus, R. G., Ferguson, A. T., Ottaviano, Y. L., Parl, F. F., Smith, H. S., Weitzman, S. A., Baylin, S. B., Issa, J-P., and Davidson, N. E. Methylation of estrogen and progesterone receptor genes 5′CpG islands correlates with lack of ER and PR gene expression in breast tumors. Clin. Cancer Res., 2: 805-810, 1996.
31. Lapidus, R. G., Nass, S. J., Butash, K. A., Parl, F. F., Weitzman, S. A., Graff, J. G., Herman, J. G., and Davidson, N. E. Mapping of the ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res., 58: 2515-2519, 1998.
32. Virmani, A. K., Rathi, A., Zochbauer-Muller, S., Sacchi, N., Fukuyama, Y., Bryant, D., Maitra, A., Heda, S., Fong, K. M., Thunnissen, F., Minna, J. D., and Gazdar, A. F. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J. Natl. Cancer Inst. (Bethesda), 92: 1303-1307, 2000.
33. Geisen, C., Denk, C., Gremm, B., Baust, C., Karger, A., Bollag, W., and Schwarz, E. High-level expression of the retinoic acid receptor β in normal cells of the uterine cervix is regulated by the retinoic acid receptor α and is abnormal down-regulated in cervical carcinoma cells. Cancer Res., 57: 1460-1467, 1997.
34. Widschwendter, M., Berger, J., Muller, H. M., Zeimet, A. G., and Marth, C. Epigenetic down-regulation of the retinoic acid receptor-β 2 gene in breast cancer. J. Mamm. Gland Biol. Neoplasia, 6: 193-201, 2001.
35. Sonnhag, C., Karlsson, E., and Hed, J. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide. Acta Med. Scand., 206: 245-251, 1979.
36. Ludden, T. M., McNay, J. L., Jr., Shepherd, A. M., and Lin, M. S. Variability of plasma hydralazine concentrations in male hypertensive patients. Arthritis Rheum., 24: 987-993, 1981.
37. Ferguson, A. T., Vertino, P. M., Spitzner, J. R., Baylin, S. B., Muller, M. T., and Davidson, N. E. Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2′deoxycytidine-induced cytotoxicity in human breast cancer cells. J. Biol. Chem., 272: 32260-32366, 1997.
38. Thomas, T. J., and Messner, R. P. Effects of lupus-inducing drugs on the B to Z transition of synthetic DNA. Arthritis Rheum., 29: 638-644, 1986.
39. Cornacchia, E., Golbus, J., Maybaum, J., Strahler, J., Hanash, S., and Richardson, B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140: 2197-2200, 1988.
40. Momparler, R. L., and Goodman, J. In vitro cytotoxic and biochemical effects of 5-aza-2′-deoxycytidine. Cancer Res., 37: 1636-1639, 1977.
41. Yamagata, M., and Tannock, I. F. The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and antitumour effects. Br. J. Cancer, 73: 1328-1324, 1996.
42. Horsman, M. R., Nordsmark, M., Hoyer, M., and Overgaard, J. Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumors. Br. J. Cancer, 72: 1474-1478, 1995.
43. Hua, J., and Pero, R. W. Toxicity, antitumor and chemosensitizing effects of 3-chloroprocainamide. Acta Oncol., 136: 811-816, 1997.
44. Esposito, M., Viale, M., Vannozzi, M. O., Zicca, A., Cadoni, A., Merlo, F., and Gogioso, L. Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II). Toxicol. Appl. Pharmacol., 140: 370-377, 1996.
45. Onishi, T., Ohishhi, Y., Goto, H., Suzuki, H., Asano, K., Hatano, T., Abe, K., Tomita, M., and Imagawa, K. Study on the combined therapy of DNA-methyltransferase inhibitor and interferon-α/β for mouse spontaneously arose renal cell carcinoma, and immunological mechanism induced by the therapy. Nippon Hinyokika Gakkai Zasshi, 89: 828-835, 1998.
46. Virmani, A. K., Muller, C., Rathi, A., Zoechbauer-Mueller, S., Mathis, M., and Gazdar, A. F. Aberrant methylation during cervical carcinogenesis. Clin. Cancer Res., 7: 584-589, 2001.
47. Dong, S. M., Kim, H. S., Rha, S. H., and Sidransky, D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res., 7: 1982-1986, 2001.
48. Rosas, S. L., Koch, W., da Costa Carvalho, M. G., Wu, L., Califano, J., Westra, W., Jen, J., and Sidransky, D. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and deathassociated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res., 61: 939-942, 2001.